Cost Analyses of an As-needed 60-actuation Vs. 120-actuation Budesonide-Formoterol pMDI for Patients With Mild Asthma From a United States Payor Perspective

被引：0

作者：

Stein, K. R. ^{[1
]}

Jost, E. ^{[2
]}

Barker, A. R. ^{[3
]}

Wojcik, K. M. ^{[4
]}

Chen, V. ^{[1
]}

Bucha, S. ^{[1
]}

Simkovich, S. M. ^{[5
]}

Goss, C. W. ^{[6
]}

Huffman, M. D. ^{[7
]}

Agarwal, M. ^{[6
]}

Sumino, K. ^{[1
]}

Castro, M. ^{[8
]}

Reddel, H. K. ^{[9
]}

Pleasants, R. ^{[10
]}

Krings, J. G. ^{[1
]}

机构：

[1] Washington Univ St Louis, Div Pulm & Crit Care Med, Sch Med, St Louis, MO USA

[2] Washington Univ St Louis, Ctr Adv Hlth Serv Policy & Amp, Econ Res, St Louis, MO USA

[3] Washington Univ St Louis, Brown Sch Social Work, St Louis, MO USA

[4] Natl Inst Hlth, Natl Inst Minor Hlth & Hlth Dispar, Bethesda, MD USA

[5] MedStar Hlth Res Inst, Div Hlth Care Delivery Res, Hyattsville, MD USA

[6] Washington Univ St Louis, Div Biostat, Sch Med, St Louis, MO USA

[7] Washington Univ St Louis, Cardiovasc Div, Sch Med, St Louis, MO USA

[8] Washington Univ St Louis, Global Hlth Ctr, Sch Med, St Louis, MO USA

[9] Univ Kansas, Pulm Crit Care & Sleep Med, Med Ctr, Kansas City, KS USA

[10] Macquarie Univ, Woolcock Inst Med Res, Sydney, NSW, Australia

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A7006

引用

页数：2

共 5 条

[1] The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada
Sadatsafavi, Mohsen
FitzGerald, J. Mark
O'Byrne, Paul M.
Soliman, Mena
Sriskandarajah, Niroshan
Vicente, Colin
Golam, Sarowar Muhammad
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2021, 17 (01):
[2] The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada
Mohsen Sadatsafavi
J. Mark FitzGerald
Paul M. O’Byrne
Mena Soliman
Niroshan Sriskandarajah
Colin Vicente
Sarowar Muhammad Golam
Allergy, Asthma & Clinical Immunology, 17
[3] Cost Analyses of a Symptom-driven Inhaled Corticosteroid-Formoterol Treatment Strategy for Patients With Mild Asthma From a United States Payor Perspective
Renaud, C. J.
Jost, E.
Barker, A. R.
Montane, B.
Simkovich, S. M.
Sumino, K.
Mcgregor, M.
Castro, M.
Bollmeier, S.
Krings, J. G.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[4] Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective
FitzGerald, J. Mark
Arnetorp, Sofie
Smare, Caitlin
Gibson, Danny
Coulton, Karen
Hounsell, Kirsty
Sadatsafavi, Mohsen
EUROPEAN RESPIRATORY JOURNAL, 2019, 54
[5] Cost-effectiveness analysis of budesonide/formoterol SMART therapy versus salmeterol/fluticasone plus as-needed SABA among patients ≥12 years with moderate asthma from the Chinese societal perspective
Zhou, Keruo
Zhang, Min
Zuo, Chenyu
Xie, Xiazhen
Xuan, Jianwei
JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 1018 - 1026

← 1 →